[A new method for treating patients with chronic prostatitis].
A new preparation is reported for treatment of chronic inflammation of the prostate, which substantially lowers rates of patients' complaints and depresses the secretion leucocyte reaction. Prostatilen was shown to be capable of normalization of immunity status of the chronic prostatitis patients thus lowering the microbial index of the cultured prostate secretion microorganisms. The following new nonantibacterial strategy of treatment of chronic prostatitis patients is proposed: prostatilen given as a single agent or in combination with immunomodulators and physiotherapeutic methods. Antibacterial therapy is to be instituted on a short-term basis only during the period of exacerbation of the inflammatory process.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000917:Antibody Formation / Q000187:drug effects; D002908:Chronic Disease; D003131:Combined Modality Therapy / Q000379:methods; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use; D026741:Physical Therapy Modalities; D011472:Prostatitis / Q000276:immunology / Q000382:microbiology / Q000628:therapy*
D000276:Adjuvants, Immunologic; D010455:Peptides; C069549:prostatilen
Novyĭ sposib likuvannia khvorykh na khronichnyĭ prostatyt.